Chemours Q1 net loss widens to $29M; adjusted EBITDA up 2% to $169M

Chemours Co

2026-Q1 EPS reported -$0.19 revenue$1,381,000,000

Net sales $1.381B, up 1% YoY; TSS segment posted record Q1 with double-digit Opteon growth.
Net loss $(29)M ($0.19/sh) vs $(5)M ($0.03/sh) YoY; adjusted net income $8M ($0.05/sh) vs $19M ($0.13/sh).
Adjusted EBITDA $169M (+2% YoY); sequential TiO2 price increased 3% in net sales.
Received ~$287M net from Kuan Yin site sale; used to pay down €140M of debt.
Volume down 4% YoY due to production constraints from an operational outage.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Chemours Co reported first quarter 2026 results: revenue $1.4 billion, net income Net Loss attributable to Chemours of $29 million, or $0.19 per diluted share, EPS $0.19 per diluted share.

Period: first quarter 2026
Revenue: $1.4 billion
Net income: Net Loss attributable to Chemours of $29 million, or $0.19 per diluted share
EPS: $0.19 per diluted share
Result: reported results

Exact text from the filing

and Advanced Performance Materials (“APM”), today announced its financial results for the first quarter 2026. Key First Quarter 2026 Results & Recent Highlights 1 • Net Sales of $1.4 billion, slightly up compared to the corresponding prior-year quarter, with TSS reporting record first quarter results, with continued double-digit year-over-year sales growth in

View on SEC.gov

4 earnings releases filed in the last 30 days. Browse all earnings releases →

Chemours Co filing history →

Source: SEC EDGAR

accession 0001627223-26-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.